Följ
David John Mott
David John Mott
Office of Health Economics
Verifierad e-postadress på ohe.org - Startsida
Titel
Citeras av
Citeras av
År
Incorporating quantitative patient preference data into healthcare decision making processes: is HTA falling behind?
DJ Mott
The Patient-Patient-Centered Outcomes Research 11 (3), 249-252, 2018
462018
Valuing EQ-5D-Y-3L health states using a discrete choice experiment: do adult and adolescent preferences differ?
DJ Mott, KK Shah, JM Ramos-Goñi, NJ Devlin, O Rivero-Arias
Medical Decision Making 41 (5), 584-596, 2021
322021
Whose preferences should be elicited for use in health-care decision-making? A case study using anticoagulant therapy
DJ Mott, M Najafzadeh
Expert Review of Pharmacoeconomics & Outcomes Research 16 (1), 33-39, 2016
212016
EQ-5D-Y Value Set for Germany
S Kreimeier, D Mott, K Ludwig, W Greiner, IHTAH Group
PharmacoEconomics, 2022
132022
Challenges in valuing temporary health states for economic evaluation: a review of empirical applications of the chained time trade-off method
J Stoniute, DJ Mott, J Shen
Value in Health 21 (5), 605-611, 2018
112018
Accounting for preference heterogeneity in discrete-choice experiments: an ISPOR special interest group report
C Vass, M Boeri, S Karim, D Marshall, B Craig, KA Ho, D Mott, ...
Value in Health 25 (5), 685-694, 2022
92022
Reporting quality of marginal rates of substitution in discrete choice experiments that elicit patient preferences
DJ Mott, N Chami, T Tervonen
Value in Health 23 (8), 979-984, 2020
92020
Conducting a time trade-off study alongside a clinical trial: a case study and recommendations
J Shen, S Hill, D Mott, M Breckons, L Vale, R Pickard
PharmacoEconomics-Open 3, 5-20, 2019
82019
A multinational European study of patient preferences for novel diagnostics to manage antimicrobial resistance
DJ Mott, G Hampson, MJ Llewelyn, J Mestre-Ferrandiz, MM Hopkins
Applied Health Economics and Health Policy 18, 69-79, 2020
52020
Public preferences for health gains and cures: a discrete choice experiment
G Hampson, D Mott, N Devlin, K Shah
Office of Health Economics, London, 2019
42019
PCN382-quality of life in long-term cancer survivors: Implications for future health technology assessments in oncology
P Cubi-Molla, DJ Mott, K Shah, M Herdman, Y Summers, C Tsuchiya, ...
Value in Health 21, S79, 2018
42018
A European, prospective, observational study of enzalutamide in patients with metastatic castration-resistant prostate cancer: PREMISE
H Payne, A Robinson, B Rappe, S Hilman, U De Giorgi, S Joniau, ...
International Journal of Cancer, 2021
32021
Does changing the age of a child to be considered in EQ-5D-Y-3L DCE based valuation studies affect health preferences?
O Rivero Arias, JM Ramos-Goñi, A Estévez Carrillo, D Rowen, D Mott, ...
Value in Health 25 (7), 2022
22022
Analytical considerations when anchoring discrete choice experiment values using composite time trade-off data: the case of EQ-5D-Y-3L
DJ Mott, NJ Devlin, S Kreimeier, R Norman, KK Shah, O Rivero-Arias
PharmacoEconomics, 1-9, 2022
12022
Criteria for developing, assessing and selecting candidate EQ-5D bolt-ons
BJ Mulhern, C Sampson, P Haywood, R Addo, K Page, D Mott, K Shah, ...
Quality of Life Research 31 (10), 3041-3048, 2022
12022
Considering Severity in Health Technology Assessment: Can We Do Better?
C Skedgel, N Henderson, A Towse, D Mott, C Green
Value in Health 25 (8), 1399-1403, 2022
12022
Resource Allocation in Public Sector Programmes: Does the Value of a Life Differ Between Governmental Departments?
P Cubi-Molla, D Mott, N Henderson, B Zamora, M Grobler, M Garau
Office of Health Economics Research Papers, 2021
12021
Do preferences differ based on respondent experience of a health issue and its treatment? A case study using a public health intervention
DJ Mott, L Ternent, L Vale
The European Journal of Health Economics, 1-11, 2022
2022
How is Quality of Life Measured for Health Technology Assessments?
D Mott, G Kumar, C Sampson, M Garau
Briefings, 2021
2021
Impact of Including Carer Information in Time Trade-Off Tasks: Results from a Pilot Study
DJ Mott, I Leslie, KK Shah, J Rowell, N Scheuer
PharmacoEconomics - Open, 2021
2021
Systemet kan inte utföra åtgärden just nu. Försök igen senare.
Artiklar 1–20